(Q34567958)

3 August 2017

1 reference

title

Vascular effects of TZDs: new implications (English)

1 reference

3 August 2017

Florian Blaschke

1

1 reference

3 August 2017

Robert Spanheimer

series ordinal

2

1 reference

3 August 2017

Mehmood Khan

series ordinal

3

1 reference

3 August 2017

Ronald E Law

series ordinal

4

1 reference

3 August 2017

publication date

5 June 2006

1 reference

3 August 2017

published in

Vascular Pharmacology

1 reference

3 August 2017

volume

45

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

3-18

1 reference

Discrimination between obesity and insulin resistance in the relationship with adiponectin

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Tissue inhibitors of metalloproteinases: evolution, structure and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Regulation of matrix metalloproteinases: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The independence of signaling pathways mediating increased expression of plasminogen activator inhibitor type 1 in HepG2 cells exposed to free fatty acids or triglycerides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin stimulates production of nitric oxide in vascular endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Expression of matrix metalloproteinases by human plasma cells and B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Plasminogen activator inhibitor-1 and the kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Coronary Plaque Disruption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin down-regulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein promotes monocyte chemoattractant protein-1--mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Vascular smooth muscle cell activation by C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

AdipoQ is a novel adipose-specific gene dysregulated in obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Inflammatory markers and risk of developing type 2 diabetes in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Hepatotoxicity of thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein: risk marker or mediator in atherothrombosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Diabetes mellitus and diabetes-associated vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Plasminogen-activator inhibitor type 1 and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Disruption of adiponectin causes insulin resistance and neointimal formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Association of hypoadiponectinemia with coronary artery disease in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

ATP-binding cassette transporter AI and its role in HDL formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Atherosclerotic plaque caps are locally weakened when macrophages density is increased

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Molecular bases of the acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Inflammation in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin and development of type 2 diabetes in the Pima Indian population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Nitric oxide and vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Low plasma adiponectin levels predict progression of coronary artery calcification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Diet-induced insulin resistance in mice lacking adiponectin/ACRP30

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Evidence for a potent antiinflammatory effect of rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Direct proinflammatory effect of C-reactive protein on human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Plasma adiponectin levels and risk of myocardial infarction in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Association between obesity and a prothrombotic state: the Framingham Offspring Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Endothelial inflammation in insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin and protection against type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction--role of neurohormones and cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Hepatotoxicity of the thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Matrix metalloproteinases, oxidative stress and the acute response to acute myocardial ischaemia and reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Atherosclerosis and the two faces of endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway:: an implication of CRP involvement in plaque destabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Pathogenesis of abdominal aortic aneurysms--cellular and biochemical mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Generation of C-reactive protein and complement components in atherosclerotic plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Global and societal implications of the diabetes epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VPH.2005.11.009

1 reference

3 August 2017

1 reference